Skip to main content
SpringerLink
Log in

Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The pharmacokinetics of intravenously infused hexobarbital was studied in 10 patients with intrahepatic cholestasis and in 9 with extrahepatic biliary obstruction. The results were compared with those obtained in 16 healthy young volunteers and 5 older patients with normal liver function. After infusion, the plasma concentrations showed a rapid initial decline (α-phase) and subsequently a slower decrease (β-phase). The half-life of a latter phase was 323±84 min in the healthy group, 357±151 min in the patients with intrahepatic cholestasis and 344±115 min in the group with biliary obstruction; the clearances were 3.41±0.90, 4.08±1.95 and 3.81±1.97 ml×min−1×kg−1, respectively. The differences were not statistically significant. The mean volume of the central compartment of distribution and the steady state volume of distribution were not significantly different. In two patients hexobarbital clearance during cholestasis was greater than after it had subsided. After treatment of 11 patients with cholestasis with drug metabolism-inducing agents (phenobarbital, rifampicin or phenytoin), the half-life of hexobarbital was significantly shortened and the mean value of hexobarbital clearance was more than doubled.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Auranen, A.: Liver involvement in cholecystitis and in obstructive icterus. Acta Chirurg. Scand. Suppl.424 (1972)

  2. Back, P.: Isolation and identification of a chenodeoxycholic acid glucuronide from human plasma in intrahepatic cholestasis. Hoppe-Seyler's Z. Physiol. Chem.357, 213–215 (1976)

    Google Scholar 

  3. Brachtel, D., Gallenkamp, H., Richter, E.: Hexobarbital-Oxidation in vivo und in vitro bei Choledochusligatur und ANIT-Cholestase der Ratte. Ztschr. Gastroenterologie15, 378–380 (1977)

    Google Scholar 

  4. Branch, R. A., Herbert, C. M., Read, A. E.: Determinants of serum antipyrine half-lives in patients with liver disease. Gut14, 569–573 (1973)

    Google Scholar 

  5. Breimer, D. D., van Rossum, J. M.: Rapid and sensitive gaschromatographic determination of hexobarbital in plasma of man using a nitrogen detector. J. Chromatogr.88, 235–243 (1974)

    Google Scholar 

  6. Breimer, D. D., Honhoff, C., Zilly, W., Richter, E., van Rossum, J. M.: Pharmacokinetics of hexobarbital in man after intravenous infusion. J. Pharmacokin. Biopharm.3, 1–11 (1975a)

    Google Scholar 

  7. Breimer, D. D., Zilly, W., Richter, E.: Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery. Clin. Pharmacol. Ther.18, 433–440 (1975b)

    Google Scholar 

  8. Breimer, D. D., Zilly, W., Richter, E.: The influence of rifampicin on drug metabolism: Differences between hexobarbital and antipyrine. Clin. Pharmacol. Ther.21, 470–481 (1977)

    Google Scholar 

  9. Conney, A. H.: Pharmacological implications of microsomal enzyme induction. Pharmacol. Rev.19, 317–366 (1967)

    Google Scholar 

  10. Drew, R., Priestly, B. G.: Hexobarbital sleeping time and drug metabolism in rats with ligated bile ducts — A lack of correlation. Biochem. Pharmacol.25, 1659–1663 (1976)

    Google Scholar 

  11. Drew, R., Priestly, B. G., O'Reilly, W. J.: Hexobarbital pharmacokinetics in rats after ligation of the common bile ducts. J. Pharmacol. Exp. Ther.201, 534–540 (1977)

    Google Scholar 

  12. Elfström, J., Lindgren, S.: Disappearance of phenazone from plasma in patients with obstructive jaundice. Eur. J. clin. Pharmacol.7, 467–471 (1974)

    Google Scholar 

  13. Fevery, J., van Damme, B., Michiels, R., De Groote, J., Heirwegh, K. P. M.: Bilirubin conjugates in bile of man and rat in the normal state and in liver disease. J. Clin. Invest.51, 2482–2491 (1972)

    Google Scholar 

  14. Gallenkamp, H., Richter, E.: Influence of α-Naphthylisocyanate (ANIT) on microsomal cytochrome P-450, protein and phospholipid content in rat liver. Biochem. Pharmacol.23, 2431–2435 (1974)

    Google Scholar 

  15. Greim, H., Trülzsch, D., Roboz, J., Dressler, K., Czygan, P., Hutterer, F., Schaffner, F., Popper, H.: Mechanism of cholestasis. IV. bile acids in normal rat livers and in those after bile duct ligation. Gastroenterology63, 837–845 (1972)

    Google Scholar 

  16. Hepner, G. W., Vesell, E. S.: Aminopyrine metabolism in the presence of hyperbilirubinemia due to cholestasis or hepatocellular disease. Clin. Pharmacol. Ther.21, 620–626 (1977)

    Google Scholar 

  17. Hutterer, F., Bacchin, P. G., Denk, H., Schenkmann, J. B., Schaffner, F., Popper, H.: Mechanism of cholestasis. II. Effect of bile acids on the microsomal biotransformation system in vitro. Life Sci.9, 1159–1166 (1970b)

    Google Scholar 

  18. Kuenzle, C. C.: Bilirubin conjugates of human bile: Isolation of phenylazo derivatives of bile bilirubin. Biochem. J.119, 387–411 (1970)

    Google Scholar 

  19. Loo, J. C. K., Riegelman, S.: Assessment of pharmacokinetic constants from postinfusion blood curves obtained after i. v. infusion. J. Pharm. Sci.59, 53–55 (1970)

    Google Scholar 

  20. Makino, I., Shinozaki, K., Nakagawa, S., Mashimo, J.: Measurement of sulfated and nonsulfated bile acids in human serum and urine. J. Lipid Res.15, 132–138 (1974)

    Google Scholar 

  21. Richter, E., Grün, M., Zilly, W., Brachtel, D., Kühn, H. A.: Arzneimittelmetabolismus bei tierexperimenteller Cholestase. Verh. Dtsch. Ges. Inn. Med.78, 1402–1404 (1972)

    Google Scholar 

  22. Richter, E., Joeres, R., Buschmann, J., Zilly, W.: Alternative transport pathways of cholephilic14C-Hexobarbital metabolites in rats with experimental hepatitis and cholestasis. Acta Hepato-Gastrologica26, 429–434 (1979)

    Google Scholar 

  23. Rossum, J. M., van: Significance of pharmacokinetics for drug design and the planning of dosage regimes. In: Drug Design I, p. 469–521, New York: Academic Press 1971

    Google Scholar 

  24. Schaffner, F., Poppjer, H.: Hypothesis: Cholestasis is the result of hypoactive hypertrophic smooth endoplasmic reticulum in the hepatocyte. Lancet1969/II, 355–359

    Google Scholar 

  25. Summerfield, J. A., Billing, B. H., Shackleton, C. H. L.: Identification of bile acids in the serum and urine in cholestasis. Evidence for 6 α-hydroxalation of bile acids in man. Biochem. J.154, 507–516 (1976)

    Google Scholar 

  26. Van Berge Henegouwen, G. P., Brandt, K.-H., Eyssen, H., Parmentier, G.: Sulphated and unsulphated bile acids in serum, bile, and urine of patients with cholestasis. Gut17, 861–869 (1976)

    Google Scholar 

  27. Zilly, W., Breimer, D. D., Richter, E.: Induction of drug metabolism in man following rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur. J. Clin. Pharmacol.9, 219–227 (1975)

    Google Scholar 

  28. Zilly, W., Breimer, D. D., Richter, E.: Stimulation of drug metabolism in patients with liver cirrhosis and cholestasis after rifampicin treatment, measured by increased hexobarbital and tolbutamide clearance. Eur. J. Clin. Pharmacol.11, 287–293 (1977)

    Google Scholar 

  29. Zilly, W., Breimer, D. D., Richter, E.: Hexobarbital disposition in compensated and decompensated liver cirrhosis. Clin. Pharmacol. Ther.23, 525–534 (1978)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Würzburg, Federal Republic of Germany

    E. Richter & W. Zilly

  2. Department of Pharmacology, Subfaculty of Pharmacy, University of Leiden, The Netherlands

    D. D. Breimer

Authors
  1. E. Richter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. D. Breimer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Zilly
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Partly supported by Grant 13-28-22 from The Netherlands Foundation for Medical Research (Fungo).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Richter, E., Breimer, D.D. & Zilly, W. Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. Eur J Clin Pharmacol 17, 197–202 (1980). https://doi.org/10.1007/BF00561900

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00561900

Key words

Search

Navigation